CA2005365A1 - Medication for the treatment or prevention of hiv virus infection through passive immunization and processes for its preparation - Google Patents

Medication for the treatment or prevention of hiv virus infection through passive immunization and processes for its preparation

Info

Publication number
CA2005365A1
CA2005365A1 CA2005365A CA2005365A CA2005365A1 CA 2005365 A1 CA2005365 A1 CA 2005365A1 CA 2005365 A CA2005365 A CA 2005365A CA 2005365 A CA2005365 A CA 2005365A CA 2005365 A1 CA2005365 A1 CA 2005365A1
Authority
CA
Canada
Prior art keywords
preparation
prevention
processes
treatment
medication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2005365A
Other languages
French (fr)
Other versions
CA2005365C (en
Inventor
Michel Grandgeorge
Francois Pelloquin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2005365A1 publication Critical patent/CA2005365A1/en
Application granted granted Critical
Publication of CA2005365C publication Critical patent/CA2005365C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Drug for the treatment or prevention by passive immunization of the HIV-infection and processes for preparation thereof. According to the invention, the drug consists of, or comprises, a preparation of anti-HIV gammaglobulins Ig6 and/or IgM of human origin without antibodies directed against glycoproteins of the HIV virus envelope and/or anti-CD4 antibodies.
CA002005365A 1988-12-15 1989-12-13 Medication for the treatment or prevention of hiv virus infection through passive immunization and processes for its preparation Expired - Fee Related CA2005365C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8816580 1988-12-15
FR8816580A FR2640511B1 (en) 1988-12-15 1988-12-15 MEDICINES FOR THE TREATMENT OR PREVENTION BY PASSIVE IMMUNIZATION OF HIV VIRUS INFECTION AND METHOD OF PREPARATION

Publications (2)

Publication Number Publication Date
CA2005365A1 true CA2005365A1 (en) 1990-06-15
CA2005365C CA2005365C (en) 1995-12-12

Family

ID=9373004

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002005365A Expired - Fee Related CA2005365C (en) 1988-12-15 1989-12-13 Medication for the treatment or prevention of hiv virus infection through passive immunization and processes for its preparation

Country Status (13)

Country Link
EP (1) EP0374053B1 (en)
JP (1) JPH03505738A (en)
CN (1) CN1045035A (en)
AT (1) ATE102836T1 (en)
AU (1) AU627540B2 (en)
CA (1) CA2005365C (en)
DE (1) DE68913932T2 (en)
DK (1) DK192990D0 (en)
ES (1) ES2062079T3 (en)
FR (1) FR2640511B1 (en)
IE (1) IE63831B1 (en)
WO (1) WO1990006773A1 (en)
ZA (1) ZA899533B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432926T2 (en) * 1993-02-05 2004-05-13 Epigen, Inc., Wellesley HUMANES CARCINOMA-ANTIGEN (HCA), HCA ANTIBODIES, HCA IMMUNOASSAYS, RECORDING METHODS AND THERAPY
CN106110422B (en) * 2016-07-01 2019-02-01 翁炳焕 AIDS immunization therapy absorber

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3604947A1 (en) * 1986-02-17 1987-08-20 Biotest Pharma Gmbh METHOD FOR PRODUCING AN IMMUNALLOBULIN-CONTAINING PREPARATE AND THE USE THEREOF FOR PROPHYLAXIS AND THERAPY OF AIDS
US4863730A (en) * 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
DE379516T1 (en) * 1987-08-11 1991-01-17 The Regents Of The University Of Minnesota, Minneapolis, Minn., Us HYPERIMMUN GLOBULIN AGAINST HIV.

Also Published As

Publication number Publication date
DE68913932D1 (en) 1994-04-21
AU627540B2 (en) 1992-08-27
WO1990006773A1 (en) 1990-06-28
JPH03505738A (en) 1991-12-12
ATE102836T1 (en) 1994-04-15
DK192990A (en) 1990-08-14
CA2005365C (en) 1995-12-12
EP0374053A1 (en) 1990-06-20
AU4806290A (en) 1990-07-10
EP0374053B1 (en) 1994-03-16
IE63831B1 (en) 1995-06-14
FR2640511B1 (en) 1993-04-23
DE68913932T2 (en) 1994-07-07
ES2062079T3 (en) 1994-12-16
IE894005L (en) 1990-06-15
CN1045035A (en) 1990-09-05
FR2640511A1 (en) 1990-06-22
DK192990D0 (en) 1990-08-14
ZA899533B (en) 1990-12-28

Similar Documents

Publication Publication Date Title
NZ335612A (en) A composition containing cytotoxic specificT-cell epitopes being either Rev and/or Tat proteins from HIV virus for prevention and treatment of human immunodeficiency virus (HIV) infection
AU3215895A (en) Human-murine chimeric antibodies against respiratory syncytial virus
CA2192512A1 (en) Nm03 antibody materials and methods
AU4985496A (en) Administration of a cyclosporine-specific monoclonal antibody that cross-reacts with hiv-1 p24 gag to treat hiv infection
CA2168583A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
EP0230574A3 (en) Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
HK1067958A1 (en) Methods for inhibiting hiv associated disease using monoclonal antibodies directed against anti-selfcytotoxic t-cells
AU8010791A (en) Hiv monoclonal antibody
EP0577243A3 (en) Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection.
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
CA2005365A1 (en) Medication for the treatment or prevention of hiv virus infection through passive immunization and processes for its preparation
AU1715292A (en) Human immunodeficiency virus-related immune preparation
AU5061090A (en) Aids therapy
EP0327648A4 (en) Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient.
CA2160696A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
FR2614025B1 (en) PEPTIDES LIKELY TO BE RECOGNIZED BY ANTIBODIES INDUCED AGAINST HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed